Ultragenyx Pharmaceutical has recently announced the appointment of Clay Siegall, Ph.D. and Mathew Fust to its Board of Directors effective January 30, 2014. Currently, Siegall serves as the President, CEO, and Chairman of Seattle Genetics while Mr. Fust is the former Chief Executive Officer and Executive Vice President of Onyx Pharmaceuticals.
Both Clay and Mathew have a track record of leadership in the biopharmaceutical industry. According to Eran Nadav, the Chairman of the Board of Ultragenyx, the two appointees bring diverse experience to Ultragenyx as it enters the next development phase. Over the past few years, Ultragenyx has made substantial progress with its clinical programs. Dr. Siegall looks forward to injecting his experience towards that development. He wants to address challenges faced by patients affected by rare and ultra-rare diseases. Mr. Fust says it’s exciting to be part of a company that not only focuses on patients but leverages an innovative approach to address life-threatening issues.
Ultragenyx is a biopharmaceutical company committed to developing novel products to help treat rare and ultra-rare diseases. Founded in 2010, Ultragenyx focuses on debilitating metabolic genetic diseases. Over the years, Ultragenyx has built a diverse portfolio of novel products to help treat diseases that have no approved therapies. The company is led by a team of experts in the development of treatment therapies for ultra-rare diseases. Its strategy is predicated upon the development of cost and time-efficient therapies for patients with urgent medical needs. Ultragenyx looks forward to delivering affordable and safe treatments to patients with emergency medical needs.
About Dr. Clay Siegall
Dr. Siegall is the current Seattle Genetics’ President, CEO, and Chairman of Board of Directors. Seattle Genetics is a biotechnology company that depends on the antibody to develop innovative cancer treatment therapies. Dr. Clay Sieagall founded Seattle Genetics in 1998. Between 1991 and 1997, Dr. Seattle Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute before joining Seattle Genetics. Previously, he used to work for National Institutes of Health between 1988 and 1991. Besides, Dr. Siegall sits on the board of Mirna Therapeutics and Alder BioPharmaceuticals.
Dr. Siegall attended the University of Maryland to pursue a Bachelor of Science in Zoology. Later on, he joined George Washington University to pursue a Ph.D. in Genetics. Under Dr. Siegall’s leadership, Seattle Genetics has built a diverse portfolio of cancer treatment therapies base on the antibody. The U.S. Food and Drug Administration recently approved, ADCETRIS, one of Seattle Genetics’ antibody-based cancer treatment therapies. Dr. Siegall has helped Seattle Genetics to secure over $675 million worth of capital through public and private financings.